[Is there progress in chemotherapy for breast cancer?].
Breast cancer is the most frequent type of cancer in women. The therapeutic approaches to breast cancer have developed rapidly over the past 20 years, due to the increasing knowledge about the biology of breast cancer. Therefore it was possible to increase response rates as well as the duration of response and survival in neoadjuvant, adjuvant, and palliative treatment. This paper gives a review of the current breast cancer trials. Effective new cytotoxic chemotherapy and hormonal therapy agents, as well as the identification of specific molecular abnormalities (HER2/neu) led to the development of targeted therapeutic interventions in the neoadjuvant, adjuvant, and palliative treatment of breast cancer. Increased understanding of the biology of breast cancer led to the development of rational therapeutic interventions, which are currently under active clinical development.
Wenzel
C
C
Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Wien, Osterreich.
Schmidinger
M
M
Huber
H
H
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001317:Austria; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D010166:Palliative Care; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000068878:Trastuzumab